TEST:

Prostatype®

"Prostatype Genomics announces that previously communicated positive results from a Spanish multicentre study with Prostatype®, have now been confirmed in a scientific journal. The study included 93 patients with prostate cancer at seven Spanish hospitals, where Prostatype® delivered significantly better prognostic performance compared to NCCN®, D'Amico and EAU for both the risk of prostate cancer-specific mortality within 10 years as well as to predict the risk of developing metastasis."

The reclassification of 19.6% of patients suggests that the P-score refines risk stratification beyond NCCN, offering a more precise distinction between favourable and unfavourable outcomes, enabling more informed treatment decisions. These findings highlight the global applicability of the P-score and its potential to improve risk assessment and personalized treatment for PCa patients worldwide.

In this Spanish cohort, the P-score outperformed traditional clinicopathological systems in predicting PCSM, development of metastasis, and pathological markers, supporting its clinical utility for more personalised PCa management.

"Prostatype Genomics announces that the company's commercial activities in the U.S. continue to develop in a positive way. The number of selected American urologists at urology clinics/hospitals who have started using Prostatype® clinically for risk classification of established prostate cancer is gradually increasing and now exceeds 10 in total. Furthermore, the company has engaged a billing partner who will handle administration and financial flows linked to reimbursement from Medicare and other healthcare insurance providers. The company's ongoing Medicare application for reimbursement is progressing, and the company is in active dialogue with Medicare to deliver the remaining clarifications requested."

"This newsletter highlights two significant achievements: positive preliminary results in the U.S. study with Prostatype® conducted with leading U.S. institutions, and that the clinical use of Prostatype® in Italy is increasing following the order received by the company in December last year. Additionally, two filmed presentations in the United States and a link to an Italian article about Prostatype® and the company’s collaborator Professor Pierluigi Bove are included."

"Prostatype Genomics is pleased to announce that preliminary results from the study conducted in the United States in collaboration with leading institutions shows promising results. Prostatype® is a genomic test designed to improve risk stratification of patients diagnosed with non-metastatic prostate cancer. The study has a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test in a patient population with multiple ethnicities."

"Prostatype Genomics AB announces that the results from the health economics study with the company's prognostic genomic test Prostatype® now has been published in the renown scientific journal PharmacoEconomics. The study and a complementary analysis, both conducted by the Institute for Health and Healthcare Economics (IHE), show that Prostatype® can contribute with just over 800 MSEK in annual health economic benefit just in Sweden compared to the method for risk classification of established prostate cancer that is currently being used in Sweden's healthcare system."

"Prostatype Genomics AB announces that the company has compiled and submitted supplementary answers in the final phase of its Medicare application to get the prognostic genomic test Prostatype® approved for reimbursement in the United States. The compilation has been conducted in an efficient manner together with external partners in Sweden and the United States to create optimal conditions to complete the application process and get Prostatype® approved for reimbursement in the near future."

The results of this study suggest that the P-score is likely to be a cost-effective alternative to D'Amico for prognostic evaluation of newly diagnosed prostate cancer in Sweden and compared with NPCR when health-related quality of life was included.

"Prostatype Genomics AB announces that the company's application for inclusion of the genomic test Prostatype® in the federal U.S. healthcare program Medicare's reimbursement system is now in its final phase. A limited number of supplementary questions have been received, and the company is working on compiling the answers which will be submitted to Medicare shortly. The company has thus taken a major step towards completing the application process and getting Prostatype® approved for reimbursement in the near future."